OCUL Ocular Therapeutix Inc
Ocular Therapeutix Inc (OCUL) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +21.2% since its last earnings release on August 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Ocular Therapeutix Inc
Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
Sector
Healthcare
Industry
Drug Delivery